The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1475
ISSUE1475
August 17, 2015
Brexpiprazole (Rexulti) for Schizophrenia and Depression
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Brexpiprazole (Rexulti) for Schizophrenia and Depression
August 17, 2015 (Issue: 1475)
The FDA has approved the oral, once-daily, second-generation
antipsychotic brexpiprazole (Rexulti –
Otsuka/Lundbeck) for treatment of schizophrenia
and as an adjunct to antidepressants for treatment
of major depressive disorder (MDD)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.